Table 3 Clinical characteristics and treatment of patients with and without major infections
CharacteristicMajor infection (n = 35)No major infection (n = 78)
Age at WG diagnosis, years (mean (SD))50.2 (13.05)47.1 (17)
Male sex, n (%)27 (77)40 (51)
Disease duration, years (mean (SD))7.85 (5.85)6.19 (4.67)
Year of diagnosis, n (%):
Before 1996 (n = 33)*16/33 (48)17/33 (52)
During/after 1996 (n = 80)19/80 (24)61/80 (74)
Main WG localisation, n (%):
Upper airways27/35 (77)66/78 (85)
Lungs24/35 (69)54/78 (69)
Kidneys20/35 (57)42/78 (54)
Ever use of the most common agents during follow-up, n (%):
CYC35/35 (100)75/78 (96)
    Intravenous35/35 (100)70/78 (90)
    Oral13/35 (37)31/78 (40)
CS35/35 (100)75/78 (96)
AZA18/35 (51)40/78 (51)
MTX9/35 (26)18/78 (23)
MMF6/35 (17)13/78 (17)
Cotrimoxazole27/35 (77)66/79 (84)
Cumulated drug doses, mean (SD):
At the end of follow-up
    CYC (g)42 (44.8)36.2 (46.6)
    CS (g)22.8 (22.3)20 (25.6)
    AZA (g)31.74 (58)55.3 (173)
    MTX (mg)465 (1340)244 (634)
    MMF (g)159.7 (554)67 (205)
Per year of follow-up
    CYC (g/year)6.57 (5.73)6.81 (7.21)
    CS (g/year)3.78 (2.74)3.82 (3.17)
    AZA (g/year)5.51 (9.83)8.24 (19.92)
    MTX (mg/year)43.5 (95.4)46.3 (143)
    MMF (g/year)24 (75.4)12.5 (43.1)
  • Only diagnosis before 1996 differed significantly (p<0.05).

  • AZA, azathioprine; CS, corticosteroid; CYC, cyclophosphamide; MMF, mycophenolate mofetil; MTX, methotrexate.